Opposite circadian rhythms in melatonin and tissue factor pathway inhibitor type 1: Does daylight affect coagulation? [6]

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 8, 2006, Pages 1840-1842

  Dahm, A ^a   Osterud B ^b   Hjeltnes, N ^c   Sandset, P M ^a   Iversen, Per Ole ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c SUNNAAS REHABILITATION HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

MELATONIN; NITRIC OXIDE; TISSUE FACTOR PATHWAY INHIBITOR;

ANALYSIS OF VARIANCE; BLOOD SAMPLING; CALCIUM HOMEOSTASIS; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMOSTASIS; HORMONAL REGULATION; HORMONE BLOOD LEVEL; HUMAN; LETTER; MALE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; QUADRIPLEGIA; SUNLIGHT; VASCULAR ENDOTHELIUM; VENOUS THROMBOEMBOLISM;

BLOOD COAGULATION; CIRCADIAN RHYTHM; ENDOTHELIUM, VASCULAR; HEMOSTASIS; HUMANS; LIGHT; LIPOPROTEINS; MELATONIN; QUADRIPLEGIA; SPINAL CORD INJURIES; TIME FACTORS;

EID: 33746604323     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.02048.x     Document Type: Letter

References (13)

1. Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: Evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci USA 1990; 87: 8869-73.
2. Warn-Cramer BJ, Rao LV, Maki SL, Rapaport SI. Modifications of extrinsic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and to inhibit factor VIIa/tissue factor: Evidence for a two-step model of inhibition. Thromb Haemost 1988; 60: 453-6.
3. Wesselschmidt R, Likert K, Girard T, Wun TC, Broze GJ Jr. Tissue factor pathway inhibitor: The carboxy-terminus is required for optimal inhibition of factor Xa. Blood 1992; 79: 2004-10.
4. Hansen JB, Huseby NE, Sandset PM, Svensson B, Lyngmo V, Nordoy A. Tissue-factor pathway inhibitor and lipoproteins. Evidence for association with and regulation by LDL in human plasma. Arterioscler Thromb 1994; 14: 223-9.
5. Dahm AE, Iversen PO, Hjeltnes N, Sandset PM. Differences in circadian variations of tissue factor pathway inhibitor type 1 between able-bodied and spinal cord injured. Thromb Res 2005; doi:10.1016/ j.thromres.2005.07.021.
6. Zeitzer JM, Ayas NT, Shea SA, Brown R, Czeisler CA. Absence of detectable melatonin and preservation of cortisol and thyrotropin rhythms in tetraplegia. J Clin Endocrinol Metab 2000; 85: 2189-96.
7. Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev 2005; 9: 11-24.
8. Dahm A, van Hylckama Vlieg A, Bendz B, Rosendaal F, Bertina RM, Sandset PM. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 2003; 101: 4387-92.
9. Johe PD, Osterud B. The in vivo effect of melatonin on cellular activation processes in human blood during strenuous physical exercise. J Pineal Res 2005; 39: 324-30.
10. (2+) homeostasis in endothelial cells. J Pineal Res 2002; 33: 37-47.
11. Wakatsuki A, Okatani Y, Ikenoue N, Shinohara K, Watanabe K, Fukaya T. Melatonin protects against oxidized low-density lipoprotein-induced inhibition of nitric oxide production in human umbilical artery. J Pineal Res 2001; 31: 281-8.
12. Bertolucci C, Pinotti M, Colognesi I, Foa A, Bernardi F, Portaluppi F. Circadian rhythms in mouse blood coagulation. J Biol Rhythms 2005; 20: 219-24.
13. Iversen PO, Dahm A, Sandset PM. Circadian variations within the hemostatic and fibrinolytic systems, with emphasis on venous thromboembolism. In: Columbus F, ed. Trend in Chronobiology Research. New York: Nova Science Publishers Inc, in press.